Brigitte Kolb Selected Research

Multiple Myeloma

1/2022	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
1/2022	Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma.
1/2021	Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study.
1/2019	Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
1/2019	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
12/2018	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
5/2018	Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
3/2016	Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
1/2016	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
5/2015	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brigitte Kolb Research Topics

Disease

20	Multiple Myeloma 01/2022 - 10/2007
1	Febrile Neutropenia 01/2019
1	Vomiting 01/2019
1	Lymphopenia (Lymphocytopenia) 01/2019
1	Residual Neoplasm 12/2018
1	Exanthema (Rash) 03/2016
1	Disease Progression 03/2016
1	Anemia 03/2016
1	Splenomegaly 01/2014
1	Ascites 01/2014
1	Venous Thromboembolism 10/2013
1	Plasmacytoma 01/2013
1	Immunoglobulin Light-chain Amyloidosis 01/2013
1	Monoclonal Gammopathy of Undetermined Significance 01/2013
1	Paraproteinemias (Monoclonal Gammopathy) 01/2013
1	Proteinuria 01/2013
1	Renal Insufficiency (Renal Failure) 01/2013
1	Leukemia 07/2012
1	Peripheral Nervous System Diseases (PNS Diseases) 11/2011
1	Intraocular Lymphoma 05/2008

Drug/Important Bio-Agent (IBA)

10	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 11/2011
9	Bortezomib (Velcade)FDA Link 01/2022 - 01/2010
8	Thalidomide (Thalomid)FDA Link 01/2021 - 10/2007
7	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 10/2007
5	Prednisone (Sone)FDA LinkGeneric 01/2019 - 10/2007
3	carfilzomibIBA 01/2022 - 05/2015
3	pomalidomideIBA 05/2018 - 03/2013
2	daratumumabIBA 01/2021 - 01/2019
2	Lenalidomide (CC 5013)FDA Link 03/2016 - 03/2013
1	EnzymesIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 12/2018
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016
1	Cytidine Monophosphate (CMP)IBA 05/2015
1	Bendamustine Hydrochloride FDA Link 02/2015
1	Hemoglobins (Hemoglobin)IBA 01/2014
1	Tryptases (Tryptase)IBA 01/2014
1	Immunomodulating AgentsIBA 10/2013
1	Blood Proteins (Serum Proteins)IBA 01/2013
1	Immunoglobulins (Immunoglobulin)IBA 01/2013
1	Methotrexate (Mexate)FDA LinkGeneric 05/2008

Therapy/Procedure

6	Stem Cell Transplantation 01/2019 - 10/2007
4	Transplantation 01/2022 - 07/2012
2	Therapeutics 01/2016 - 11/2011
1	Autologous Transplantation 07/2012
1	Drug Therapy (Chemotherapy) 05/2008
1	Combination Drug Therapy (Combination Chemotherapy) 10/2007